# A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

> **NCT02450331** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 809 (actual)

## Conditions studied

- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT02450331
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-05
- **Primary completion:** 2019-11-30
- **Final completion:** 2022-06-14
- **Target enrollment:** 809 (ACTUAL)
- **Why stopped:** Sponsor decided to terminate the study early because the study did not meet its primary endpoint and because the study had met its goals of providing safety and additional exploratory efficacy information for atezolizumab monotherapy in MIBC.
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450331, "A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02450331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*